PreTRM Volume Jumps 54% as Medicaid Coverage Expands
Diagnostics firms and prenatal providers should track whether state Medicaid coverage for PreTRM spreads beyond Florida.
Updated on Nov. 5, 2026 in Economic Indicators
Sera Prognostics reported third quarter 2026 results, showing PreTRM test volume up 54% sequentially and ordering providers up 34%, while Florida became the second state to cover the test under Medicaid. Utah-based operators in diagnostics and prenatal care should note the company's shift from evidence generation to commercial execution.
Why it matters
The company is moving from clinical evidence generation into commercial sales, with a scaled sales organization built for an anticipated fiscal 2027 volume ramp. Medicaid reimbursement with established fee schedule pricing in a second state is the kind of payer signal that determines whether a new diagnostic can scale.
Sera Prognostics reported third quarter 2026 revenue of $42 thousand against a net loss of $8,053 thousand, or $0.16 per share, with PreTRM test volume up 54% sequentially and ordering providers up 34%. The company's own figures show growth from a very small revenue base, and the filing does not yet show when that volume will convert to meaningful sales.
The players
Sera Prognostics
A Salt Lake City diagnostics company whose PreTRM test assesses preterm birth risk during weeks 18 to 21 of pregnancy, and which is now moving into commercial sales.
Florida Medicaid program
The state Medicaid program that became the second state to cover the PreTRM test, with established fee schedule pricing.
March of Dimes
A national maternal and infant health nonprofit whose preterm birth grading of the United States, a D+, frames the clinical need for prenatal risk testing.
The details
Sera Prognostics has moved from evidence generation toward commercial execution, scaling its commercial organization ahead of an anticipated test volume ramp in fiscal 2027. Florida's Medicaid coverage for PreTRM, with established fee schedule pricing, gives the test a reimbursement path in a second state, and the company is planning Medicaid managed care contracting in Illinois. In Europe, the company has started its CE Mark submission for PreTRM Global, and PreTRM is referenced in European Association for Perinatal Medicine guidelines.
Timeline
December 31, 2025: Balance sheet comparison date for year-end 2025.
September 30, 2026: Third quarter 2026 period end and balance sheet date.
November 4, 2026: Third quarter 2026 results announced and conference call held.
Fiscal year 2027: Anticipated test volume ramp and planned pilot initiation.
Market Landscape
Each state Medicaid program decides coverage for a diagnostic separately, so a second state covering PreTRM is a payer milestone rather than a national reimbursement change. The filing places the company in an early commercial stage where state-level payer decisions, plus the European CE Mark process, are the main drivers of market access.
Operators in diagnostics, prenatal care, and Medicaid-dependent practices should watch whether state coverage decisions for PreTRM spread beyond Florida, since that determines reimbursement breadth. Finance and procurement teams should treat the company's growth figures as early-stage, given the small revenue base and continuing losses.
The takeaway
Sera Prognostics is shifting from clinical evidence to commercial sales, so the signal to track is whether state Medicaid coverage and volume growth convert into revenue in the next several quarters. Operators evaluating prenatal testing should monitor Medicaid coverage decisions in their own states before assuming reimbursement.
What happens next
Sera Prognostics plans to begin Medicaid managed care plan contracting in Illinois and to advance the CE Mark submission for PreTRM Global, with a fiscal 2027 volume ramp anticipated.
Further reading
For context on the company's financial and market signals, see Economic Indicators in Utah.
Source note: This article includes information reported by Mohave Valley Daily News.
